Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2015

01-10-2015 | Research Article

Non-prescription treatment of NSAID induced GORD by Australian pharmacies: a national simulated patient study

Authors: Brett MacFarlane, Andrew Matthews, Jenny Bergin

Published in: International Journal of Clinical Pharmacy | Issue 5/2015

Login to get access

Abstract

Background Patients regularly present to community pharmacies for advice about and treatment for reflux symptoms and NSAIDs are a common cause of these symptoms. There is no published literature detailing the approach that pharmacies take to these enquiries, the pharmacotherapy they recommend or whether they contribute to the safe and effective use of reflux medicines. Objectives To assess in an observational study design the clinical history gathering, recommendations for GORD management and counselling provided by community pharmacies in a simulated patient scenario involving suspected NSAID induced reflux symptoms. Setting Australian community pharmacies. Method Simulated patients visited 223 community pharmacies to request treatment for reflux symptoms. The interaction was audiotaped and assessed against guidelines for the treatment of reflux symptoms. Main outcome measures Alignment of community pharmacies with international expert gastroenterologist guidance and national professional practice guidelines for the treatment of reflux symptoms by pharmacists including: consultation with a pharmacist; confirmation of reflux diagnosis based on symptoms; recommendation of short courses proton pump inhibitor (PPI) therapy; advice on the safe and effective use of reflux medicines and referral to a doctor for further assessment. Results Pharmacists consulted with the simulated patient in 77 % of cases. Symptoms were enquired about in 95 % of cases and a medicines history taken in 69 % of cases. Recommendations for treatment included: PPIs (18 %), histamine H2 antagonists (57 %) and antacids (19 %). Advice on product use was given in 83 % of cases. Referral to a doctor to discuss reflux symptoms was made in 63 % of cases. Conclusion When assessing patients for the symptoms of GORD, Australian pharmacists and non-pharmacist support staff take a comprehensive history including symptomatology, duration of symptoms, concomitant medicines and medical conditions and any GORD treatments previously trialled. They provide comprehensive counselling on the use of antisecretory and antacid medicines. Counselling could involve more comprehensive information on lifestyle approaches for GORD management and side effects of antisecretory and antacid medicines. Further alignment with guidelines for the management of GORD would result in greater referral to a doctor for assessment of recurrent GORD and greater recommendation of PPIs for symptoms. However alignment with guidelines by all pharmacists is unrealistic if the guidelines are not universally available to them.
Literature
1.
go back to reference Loffeld RJ. Gastro-oesophageal reflux disease-experience in daily practice: symptoms and symptom assessment. Scand J Gastroenterol Suppl. 2006;243:3–6.CrossRefPubMed Loffeld RJ. Gastro-oesophageal reflux disease-experience in daily practice: symptoms and symptom assessment. Scand J Gastroenterol Suppl. 2006;243:3–6.CrossRefPubMed
2.
go back to reference Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol. 2005;40(3):275–85.CrossRefPubMed Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol. 2005;40(3):275–85.CrossRefPubMed
3.
go back to reference Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano–Monghidoro study. Gut. 2008;57(10):1354–9.CrossRefPubMed Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano–Monghidoro study. Gut. 2008;57(10):1354–9.CrossRefPubMed
4.
go back to reference Liker HR, Ducrotté P, Malfertheiner P. Unmet medical needs among patients with gastroesophageal reflux disease: a foundation for improving management in primary care. Dig Dis. 2009;27(1):62–7.CrossRefPubMed Liker HR, Ducrotté P, Malfertheiner P. Unmet medical needs among patients with gastroesophageal reflux disease: a foundation for improving management in primary care. Dig Dis. 2009;27(1):62–7.CrossRefPubMed
5.
go back to reference Ruszniewski P, Soufflet C, Barthélémy P. Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study. Aliment Pharmacol Ther. 2008;28(9):1134–9.CrossRefPubMed Ruszniewski P, Soufflet C, Barthélémy P. Nonsteroidal anti-inflammatory drug use as a risk factor for gastro-oesophageal reflux disease: an observational study. Aliment Pharmacol Ther. 2008;28(9):1134–9.CrossRefPubMed
6.
go back to reference Martín-De-Argila C, Martínez-Jiménez P. Epidemiological study on the incidence of gastroesophageal reflux disease symptoms in patients in acute treatment with NSAIDs. Expert Rev Gastroenterol Hepatol. 2013;7(1):27–33.CrossRefPubMed Martín-De-Argila C, Martínez-Jiménez P. Epidemiological study on the incidence of gastroesophageal reflux disease symptoms in patients in acute treatment with NSAIDs. Expert Rev Gastroenterol Hepatol. 2013;7(1):27–33.CrossRefPubMed
7.
go back to reference Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5:CD002095. doi:10.1002/14651858.CD002095.pub5.PubMed Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5:CD002095. doi:10.​1002/​14651858.​CD002095.​pub5.PubMed
8.
go back to reference Zhang JX, Ji MY, Song J, Lei HB, Qiu S, Wang J, et al. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J Gastroenterol. 2013;19(45):8408–19.PubMedCentralCrossRefPubMed Zhang JX, Ji MY, Song J, Lei HB, Qiu S, Wang J, et al. Proton pump inhibitor for non-erosive reflux disease: a meta-analysis. World J Gastroenterol. 2013;19(45):8408–19.PubMedCentralCrossRefPubMed
9.
go back to reference Holtmann G, Bigard MA, Malfertheiner P, Pounder R. Guidance of the use of over the counter proton pump inhibitors for the treatment of GORD. Int J Clin Pharm. 2011;33(3):493–500.CrossRefPubMed Holtmann G, Bigard MA, Malfertheiner P, Pounder R. Guidance of the use of over the counter proton pump inhibitors for the treatment of GORD. Int J Clin Pharm. 2011;33(3):493–500.CrossRefPubMed
10.
go back to reference Bundeff AW, Zaiken K. Impact of clinical pharmacists’ recommendations on a proton pump inhibitor taper protocol in an ambulatory care practice. J Manag Care Pharm. 2013;19(4):325–33.PubMed Bundeff AW, Zaiken K. Impact of clinical pharmacists’ recommendations on a proton pump inhibitor taper protocol in an ambulatory care practice. J Manag Care Pharm. 2013;19(4):325–33.PubMed
11.
go back to reference Atkins R, Smith L. Impact of pharmacy intervention on the use of proton pump inhibitors in the hospital setting. Consult Pharm. 2013;28(12):786–92.CrossRefPubMed Atkins R, Smith L. Impact of pharmacy intervention on the use of proton pump inhibitors in the hospital setting. Consult Pharm. 2013;28(12):786–92.CrossRefPubMed
12.
go back to reference Branham AR, Katz AJ, Moose JL, et al. Retrospective analysis of estimated cost avoidance following pharmacist provided medication therapy management services. J Pharm Pract. 2013;26(4):420–7.CrossRefPubMed Branham AR, Katz AJ, Moose JL, et al. Retrospective analysis of estimated cost avoidance following pharmacist provided medication therapy management services. J Pharm Pract. 2013;26(4):420–7.CrossRefPubMed
13.
go back to reference Benrimoj SI, Werner JB, Raffaele C, Roberts AS. A system for monitoring quality standards in the provision of non-prescription medicines from Australian community pharmacies. Pharm World Sci. 2008;30:147–53.CrossRefPubMed Benrimoj SI, Werner JB, Raffaele C, Roberts AS. A system for monitoring quality standards in the provision of non-prescription medicines from Australian community pharmacies. Pharm World Sci. 2008;30:147–53.CrossRefPubMed
15.
go back to reference Kashyap KC, Nissen LM, Smith SS, Kyle G. Management of over the counter insomnia complaints in Australian community pharmacies: a standardised patient study. Int J Pharm Pract. 2014;22:125–34.CrossRefPubMed Kashyap KC, Nissen LM, Smith SS, Kyle G. Management of over the counter insomnia complaints in Australian community pharmacies: a standardised patient study. Int J Pharm Pract. 2014;22:125–34.CrossRefPubMed
16.
go back to reference Queddeng K, Chaar B, Williams K. Emergency contraception in Australian community pharmacies: a simulated patient study. Contraception. 2011;83(2):176–82.CrossRefPubMed Queddeng K, Chaar B, Williams K. Emergency contraception in Australian community pharmacies: a simulated patient study. Contraception. 2011;83(2):176–82.CrossRefPubMed
17.
go back to reference Schneider CR, Emery L, Brostek R, Clifford RM. Evaluation of the supply of antifungal medication for the treatment of vaginal thrush in the community pharmacy setting: a randomized controlled trial. Pharm Pract (Granada). 2013;11(3):132–7.CrossRef Schneider CR, Emery L, Brostek R, Clifford RM. Evaluation of the supply of antifungal medication for the treatment of vaginal thrush in the community pharmacy setting: a randomized controlled trial. Pharm Pract (Granada). 2013;11(3):132–7.CrossRef
18.
go back to reference Schneider CR, Gudka S, Fleischer L, Clifford RM. The use of a written assessment checklist for the provision of emergency contraception via community pharmacies: a simulated patient study. Pharm Pract (Granada). 2013;11(3):127–31.CrossRef Schneider CR, Gudka S, Fleischer L, Clifford RM. The use of a written assessment checklist for the provision of emergency contraception via community pharmacies: a simulated patient study. Pharm Pract (Granada). 2013;11(3):127–31.CrossRef
Metadata
Title
Non-prescription treatment of NSAID induced GORD by Australian pharmacies: a national simulated patient study
Authors
Brett MacFarlane
Andrew Matthews
Jenny Bergin
Publication date
01-10-2015
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 5/2015
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-015-0129-9

Other articles of this Issue 5/2015

International Journal of Clinical Pharmacy 5/2015 Go to the issue